Levetiracetam
- Generic Name
- Levetiracetam
- Brand Names
- Elepsia, Keppra, Matever, Roweepra, Spritam, Levetiracetam Accord, Levetiracetam Teva, Levetiracetam Actavis, Levetiracetam ratiopharm, Levetiracetam Sun, Levetiracetam Actavis Group, Levetiracetam Hospira
- Drug Type
- Small Molecule
- Chemical Formula
- C8H14N2O2
- CAS Number
- 102767-28-2
- Unique Ingredient Identifier
- 44YRR34555
- Background
Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs). Levetiracetam possesses a wide therapeutic index and little-to-no potential t...
- Indication
Levetiracetam is indicated as an adjunctive therapy in the treatment of partial onset seizures in epileptic patients who are one month of age and older. Additionally, it is indicated as an adjunct in the treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy who are 12 years of age and older, and in primary generalized tonic-clonic seiz...
- Associated Conditions
- Epilepsies, Generalized Tonic-Clonic Seizures, Partial-Onset Seizures, Myoclonic seizures
- Associated Therapies
- -
Short Versus Long-term Levetiracetam in Brain Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Tata Memorial Centre
- Target Recruit Count
- 604
- Registration Number
- NCT06442748
- Locations
- 🇮🇳
Tata Memorial Centre, Mumbai, Maharashtra, India
Levetiracetam Versus Valproate in Idiopathic Generalized Epilepsy
- Conditions
- Interventions
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Mazandaran University of Medical Sciences
- Target Recruit Count
- 169
- Registration Number
- NCT06393309
- Locations
- 🇮🇷
Bu Ali Sina Hospital, Sari, Mazandaran, Iran, Islamic Republic of
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06345495
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Investigating the Effect of a Single-dose of Levetiracetam on Brain Function, Chemistry and Cognitive Performance in Psychosis Risk
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- King's College London
- Target Recruit Count
- 36
- Registration Number
- NCT06224530
- Locations
- 🇬🇧
King's College London, London, United Kingdom
Antiseizure Medication in Seizure Networks at Early Acute Brain Injury
- Conditions
- Interventions
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 54
- Registration Number
- NCT06081283
- Locations
- 🇺🇸
UNC Health, Chapel Hill, North Carolina, United States
Efficacy of Phenytoin vs Levetiracetam in Status Epilepticus at Institute of Child Health,Faisalabad
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Shaheed Zulfiqar Ali Bhutto Medical University
- Target Recruit Count
- 70
- Registration Number
- NCT06067412
- Locations
- 🇵🇰
Children Hopsital Faisalabad, Faisalābad, Punjab, Pakistan
Levetiracetam Prophylaxis in Brain Tumor Resection Pilot
- Conditions
- Interventions
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Hamilton Health Sciences Corporation
- Target Recruit Count
- 70
- Registration Number
- NCT05897658
Intermittent Levetricetam in Treatment of Febrile Convulsions
- Conditions
- Interventions
- First Posted Date
- 2023-05-16
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 100
- Registration Number
- NCT05860153
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
- Conditions
- Interventions
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 150
- Registration Number
- NCT05735717
- Locations
- 🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
Physiological-based Pharmacokinetics Approach to Medication Exposure During Pregnancy and Breastfeeding
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Page B. Pennell, MD
- Target Recruit Count
- 60
- Registration Number
- NCT05450978
- Locations
- 🇺🇸
Kaufmann Medical Building, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.